Clinical trials
Pediatric Oncology clinical trials
Below are recruiting pediatric oncology clinical trials, each written for real people, not researchers. We’re tracking 68 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04425434Recruiting
Treatment plan study for children with retinoblastoma
This trial looks at care recommendations for children with retinoblastoma (a childhood eye cancer). It may help standardize the best treatment approach for different patterns of tumor spread.
OuagadougouAges Up to 18 years - NCT04794296Recruiting
Care plan for children newly diagnosed with acute lymphoblastic leukemia
This trial uses a standard treatment plan for children who have just been diagnosed with acute lymphoblastic leukemia (ALL). It aims to guide the best initial treatment for certain cell types of ALL and help improve outcomes while avoiding specific higher-risk subtypes.
AbidjanAges Up to 18 years - NCT05270096Recruiting
Matches children and young people to leukemia treatment plans
This trial is set up to review tumor lab test results to help doctors choose the most appropriate next treatment for people with leukemia that has returned or did not respond. It mainly matters for younger patients who are not already on a standard treatment path.
GhentAges birth–25 years - NCT05272293RecruitingPhase 1/Phase 2
Immunotherapy using donor immune cells for young people with AML
This trial tests a new cancer treatment made from a close family member’s immune cells, adjusted in the lab and given to children or young adults with AML. It may help the immune system better attack leukemia, especially for high-risk, relapsed, or refractory AML.
Minsk, Minsk OblastAges 6 months–30 years - NCT05306509Recruiting
Early palliative care talks for kids with cancer
This trial tests whether nurse-led conversations about comfort and support (palliative care) early in a child’s cancer journey can help families and the child cope better. It is focused on newly diagnosed or relapsed pediatric cancer patients in Chinese-speaking settings.
Shanghai, MinhangAges Up to 18 years - NCT05333302RecruitingPhase 1
CAR-T treatment study for children and young adults with CD19 leukemia
This Phase 1 study tests a CAR-T cell treatment made to target CD19 in children and young adults whose leukemia or lymphoma has come back or did not respond to prior treatment. It aims to see how the treatment works and how safe it is in this age group.
Minsk, Minsk OblastAges 1–30 - NCT05334693RecruitingPhase 1/Phase 2
Donor immune cells to help prevent AML return after treatment
This study tests an “immune cell therapy” made from a family donor to help children and young adults with AML stay in remission after chemotherapy. It may help reduce the chance that AML comes back, but eligibility depends on remission status, donor suitability, and avoiding certain infections or liver issues.
Minsk, Minsk OblastAges 6 months–21 years - NCT05658640RecruitingPhase 1/Phase 2
Testing trametinib and steroid plus chemo for relapsed blood cancers
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
ViennaAges 1–21 - NCT05745714RecruitingPhase 1/Phase 2
Targeted triple-combination treatment for children with relapsed blood cancers
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
ViennaAges 1–21 - NCT05751044RecruitingPhase 1/Phase 2
Study of four medicines for children with difficult blood cancers
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
ViennaAges 1–21 - NCT05754840RecruitingPhase 1/Phase 2
Cannabinoid treatment for children with hard-to-treat cancers
This early-phase study tests whether a cannabinoid medicine (including nabilone/cannabis-based treatment) can be given safely to children and teens with relapsed or refractory cancer. It may help with treatment options for children whose cancer has come back or did not respond to standard therapy.
Vancouver, British ColumbiaAges 4–18 - NCT05867186Recruiting
Get fit during childhood cancer treatment and aftercare
This trial tests a “fit to fight” program to help children and teens stay active during and after cancer treatment. It aims to support physical and possibly emotional well-being while treatment is happening, based on whether your care team thinks it’s safe and helpful for you.
Mainz, Rhineland-PalatinateAges 3–21 - NCT06019130RecruitingPhase 2
Nivolumab for newly diagnosed nasopharyngeal cancer
This trial tests whether the immunotherapy drug nivolumab (Opdivo) can help treat nasopharyngeal cancer in both children and adults. It is for people who have just been diagnosed and have not yet received any cancer treatment.
AachenAges 3 years+ - NCT06293677RecruitingPhase 4
Antibiotic Dosing for Kids With Cancer and Fever
This study tests whether adjusting antibiotic doses based on how fast your kidneys clear the medicine can better treat infections in children with cancer who have a fever and low white blood cells (neutropenia). It aims to improve recovery and reduce side effects.
Lausanne, Canton of VaudAges 2 months–18 years - NCT05327894RecruitingPhase 3
Infants with a specific leukemia genetic change
This study tests a treatment plan for babies under 1 year with leukemia that has a KMT2A gene rearrangement. It may help by trying to improve outcomes in this high-risk group, sometimes using a drug called blinatumomab (depending on eligibility).
Buenos AiresAges 1 day–1 year - NCT06485947RecruitingPhase 1
Study testing dinutuximab beta with chemotherapy for neuroblastoma
This trial combines the immunotherapy drug dinutuximab beta with two different chemotherapy regimens to see if it works better for children with high-risk neuroblastoma that has spread. It may be an option for newly diagnosed patients who have not had cancer treatment before.
Utrecht, UtrechtAges 1.5 years–18 years - NCT07399821RecruitingPhase 1/Phase 2
Imaging study of anti-GD2-800CW in neuroblastoma
This trial tests a special dye (anti-GD2-800CW) that lights up neuroblastoma cells during surgery, helping surgeons see and remove more of the tumor. It is for children with neuroblastoma who are scheduled to have surgery.
UtrechtAges 1–18 - NCT07522905Recruiting
Virtual Movement Therapy for Kids With Leukemia in Remission
This study tests a fun virtual movement program where children who have finished leukemia treatment exercise together with a healthy friend online. The goal is to help improve their physical strength, coordination, and social skills after cancer treatment.
BratislavaAges 5–12 - NCT07606170Enrolling by invitation
Cancer Fatigue and Daily Life in Children and Teens
This study looks at how tiredness from cancer treatment affects children's and teens' quality of life and ability to do everyday activities. By understanding this better, doctors hope to help young cancer patients feel better and stay more active during and after treatment.
Istanbul, IstanbulAges 2–18 - NCT05029531RecruitingPhase 3
Immuno-chemotherapy for infants with B-lineage ALL
This trial tests a combination of medicines (immunotherapy plus chemotherapy) in babies diagnosed with a type of leukemia called B-lineage acute lymphoblastic leukemia (ALL). It aims to improve how well treatment works and is delivered safely in very young children.
Moscow, Samory-Mashela,1Ages 1 day–12 months - NCT07375563RecruitingPhase 3
Chemoimmunotherapy with NK cells for high-risk neuroblastoma
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
MoscowAges 1.5 years–18 years - NCT05549167RecruitingPhase 3
Sirolimus for children with juvenile nasal blood tumors
This trial tests whether sirolimus can shrink or control juvenile nasopharyngeal angiofibroma in children and teens, and checks its safety. It may help families who cannot rely only on surgery, especially for larger or hard-to-treat tumors.
MoscowAges 7–18 - NCT06199427RecruitingPhase 2
Preventing graft-versus-host disease after stem cell transplant for immune disorders
This trial tests a combination of two drugs, ruxolitinib and PTCy, to prevent graft-versus-host disease (a common complication) in children receiving a stem cell transplant for inborn errors of immunity. The goal is to make the transplant safer and more effective.
MoscowAges birth–21 years - NCT05518383RecruitingPhase 4
Pediatric B-cell lymphoma treatment study using established care
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
Moscow, RFAges 1 day–18 years
Hear when a new Pediatric Oncology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pediatric oncology?
- Yes. Clin2 currently lists 68 recruiting pediatric oncology studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pediatric oncology trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pediatric oncology trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.